SLCO1B3 and neoplasm: This is consistent with both preclinical cell line studies which showed OATP1B3 was the second most differentially expressed transporter between androgen-sensitive and CRPC cell lines, and tumor tissue studies which showed almost fourfold higher OATP1B3 expression between primary prostate and mCRPC tumors5,7.